Home/Indications/Cardiovascular/Heart Failure

Heart Failure

Cardiovascular 2 original drugs

Novel Drugs

Reformulations

Drug Targets

Cardiovascular indication. Heart Failure has 2 FDA-approved novel treatments, led by Roche, with 288 active industry clinical trials across 22 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Heart Failure Market Leaders

Companies with the most FDA-approved novel Heart Failure drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q2 2027

balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg

AstraZeneca

Estimated · aging NCT06307652

Q2 2027

HiCM-188 therapy

HELP Therapeutics Co., Ltd.

Estimated · aging NCT07496372

Q3 2027

furosemide infusion

Reprieve Cardiovascular, Inc

Estimated · aging NCT06898515

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Heart Failure Treatments by Mechanism

Top 12 mechanisms across 26 industry trials with a known mechanism of action.

See full pipeline →

Transferrin

1 trials 1 active 1 sponsor

Thyroid Hormone Receptor beta Agonist

1 trials 1 active 1 sponsor

Sodium-Glucose Cotransporter 2 Inhibitor

8 trials 2 sponsors

SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose

5 trials 1 sponsor

Vasopressin V2 Receptor Antagonist

3 trials 2 sponsors

Soluble Guanylate Cyclase Stimulator

2 trials 1 sponsor

ACE

1 trials 1 sponsor

Prostaglandin Analog

1 trials 1 sponsor

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

1 trials 1 sponsor

Factor Xa Inhibitor

1 trials 1 sponsor

Aldosterone Antagonist

1 trials 1 sponsor

Dihydropyridine Calcium Channel Blocker

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Heart Failure Clinical Pipeline by Phase

431 industry-sponsored trials across 161 sponsors

View full landscape →

Showing 45 of 45 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
CMP Development, LLC	Spironolactone Oral Suspension	—	NOT YET RECRUITING	2028-06	NCT06021860
Novartis	Sacubitril/valsartan	—	COMPLETED	2025-03-16	NCT04023227
Bayer	Vericiguat (Verquvo, BAY1021189)	—	COMPLETED	2024-09-19	NCT05658458
Novartis	sacubitril/valsatran	—	COMPLETED	2022-03-23	NCT03300427
Vifor (International) Inc.	ferric carboxymaltose	—	COMPLETED	2020-07-21	NCT02937454
Novartis	LCZ696	—	COMPLETED	2019-11-25	NCT02768298
AstraZeneca	Saxagliptin	—	COMPLETED	2019-08-23	NCT02917031
Amgen	Ivabradine	—	COMPLETED	2019-04-19	NCT03456856
Abbott Medical Devices	Warfarin	—	COMPLETED	2019-02-21	NCT02836652
Novartis	LCZ696 (sacubitril/valsartan)	—	COMPLETED	2018-12-13	NCT02874794
Novartis	LCZ696 (sacubitril/valsartan)	—	COMPLETED	2018-10-22	NCT02887183
Novartis	sacubitril/valsartan (LCZ696)	—	COMPLETED	2018-06-29	NCT02554890
Novartis	sacubitril/valsartan (LCZ696)	—	COMPLETED	2018-03-19	NCT02970669
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	Shenfu Zhusheye	—	COMPLETED	2017-03-24	NCT02135835
Biotronik SE & Co. KG	—	—	COMPLETED	2017-03	NCT00643188
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2015-12	NCT01434615
Biotronik SE & Co. KG	—	—	COMPLETED	2015-06	NCT01711281
ResMed	—	—	COMPLETED	2015-04	NCT01164592
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2014-11	NCT00769457
Chong Kun Dang Pharmaceutical	Candemore tablet	—	COMPLETED	2014-10	NCT01682564
Otsuka Pharmaceutical Co., Ltd.	Tolvaptan	Vasopressin V2 Receptor Antagonist [EPC]	COMPLETED	2014-03	NCT01439009
GE Healthcare	AdreView (Iobenguane I 123 Injection)	—	COMPLETED	2014-02	NCT01936649
Biotronik Japan, Inc.	—	—	COMPLETED	2014-02	NCT01221649
Vifor Pharma	Ferinject (ferric carboxymaltose)	—	COMPLETED	2014-02	NCT01453608
JW Pharmaceutical	pitavastatin	—	COMPLETED	2013-05	NCT00701285
Novartis	vildagliptin	—	COMPLETED	2012-08	NCT00894868
Merck KGaA, Darmstadt, Germany	Low Dose Bisoprolol	—	COMPLETED	2012-08	NCT01074307
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2012-07	NCT00821938
Abbott Medical Devices	—	—	COMPLETED	2012-04	NCT01295840
Biotronik SE & Co. KG	—	—	COMPLETED	2012-01	NCT00711360
Abbott Medical Devices	—	—	COMPLETED	2011-04	NCT00964938
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2011-03	NCT00847288
Medtronic Italia	—	—	COMPLETED	2010-10	NCT01109641
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2010-07	NCT01104558
Boston Scientific Corporation	—	—	COMPLETED	2010-07	NCT00677014
Novartis	ACEI/ARB	—	TERMINATED	2023-06-08	NCT04491136
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	TERMINATED	2018-12-26	NCT03026088
Korea Otsuka Pharmaceutical Co., Ltd.	Tolvaptan	Vasopressin V2 Receptor Antagonist [EPC]	TERMINATED	2017-01	NCT02352285
Ferrer Internacional S.A.	torasemide-PR	—	TERMINATED	2012-10	NCT01549158
Medtronic Cardiac Rhythm and Heart Failure	—	—	TERMINATED	2012-03	NCT00839566
LivaNova	—	—	TERMINATED	2011-09	NCT01170624
Sarfez Pharmaceuticals, Inc.	Extended Release Torsemide Tablets	—	WITHDRAWN	2026-09-16	NCT06995144
Sarfez Pharmaceuticals, Inc.	torsemide	—	WITHDRAWN	2025-03-25	NCT06708611
Ascension Health	Lisinopril	ACE	WITHDRAWN	2018-12-15	NCT03392740
Abbott Medical Devices	—	—	WITHDRAWN	2016-01	NCT02421549

Showing 100 of 110 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AstraZeneca	balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg	—	RECRUITING	2027-04-16	NCT06307652
HELP Therapeutics Co., Ltd.	HiCM-188 therapy	—	RECRUITING	2027-06-30	NCT07496372
Reprieve Cardiovascular, Inc	furosemide infusion	—	RECRUITING	2027-08	NCT06898515
Cytokinetics	Omecamtiv Mecarbil (OM)	—	RECRUITING	2027-09	NCT06736574
Pharmacosmos A/S	Ferric Derisomaltose	Transferrin	RECRUITING	2027-12-01	NCT06929806
Boehringer Ingelheim	vicadrostat	—	RECRUITING	2028-05-22	NCT06424288
Tasly Pharmaceutical Group Co., Ltd	Qishen Yiqi Dripping Pills 2 bags	—	RECRUITING	2028-06-22	NCT07687186
Amgen	Maridebart cafraglutide	—	RECRUITING	2028-06-30	NCT07037459
Boehringer Ingelheim	vicadrostat	—	RECRUITING	2029-02-04	NCT06935370
Novo Nordisk	NNC0487-0111	—	RECRUITING	2029-07-23	NCT07567001
Merck	Vericiguat tablet	—	RECRUITING	2029-08-20	NCT05714085
AstraZeneca	Elecoglipron	—	RECRUITING	2029-09-03	NCT07761117
Bayer	Finerenone (Kerendia, BAY94-8862)	—	RECRUITING	2029-11-30	NCT07188805
AstraZeneca	Baxdrostat and dapagliflozin	—	RECRUITING	2029-12-17	NCT06677060
Bayer	Finerenone (Kerendia, BAY94-8862)	—	RECRUITING	2030-12-30	NCT07192952
Novo Nordisk	Ziltivekimab	—	ACTIVE NOT RECRUITING	2026-10-01	NCT06200207
Pulnovo Medical (Wuxi) Co., Ltd.	Guideline-directed medical therapy (GDMT) for heart failure	—	ACTIVE NOT RECRUITING	2025-08-27	NCT05824923
Biopeutics Co., Ltd	Alprostadil	Prostaglandin Analog [EPC]	NOT YET RECRUITING	2029-11	NCT00610051
BioCardia, Inc.	Autologous cell therapy	—	COMPLETED	2025-02	NCT02438306
Merck	Vericiguat	Soluble Guanylate Cyclase Stimulator [EPC]	COMPLETED	2024-11-20	NCT05093933
Zensun Sci. & Tech. Co., Ltd.	Neucardin	—	COMPLETED	2024-08-30	NCT05949801
Novartis	sacubitril/valsartan	—	COMPLETED	2024-08-14	NCT06149104
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2024-07-02	NCT04847557
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2024-05-15	NCT04435626
AstraZeneca	AZD4831	—	COMPLETED	2024-03-27	NCT04986202
Novartis	sacubitril/valsartan	—	COMPLETED	2023-12-29	NCT03785405
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2023-07-05	NCT04564742
American Regent, Inc.	Ferric Carboxymaltose	—	COMPLETED	2023-02-02	NCT03037931
Novartis	sacubitril/valsartan	—	COMPLETED	2022-12-14	NCT03988634
Novartis	LCZ696	—	COMPLETED	2022-05-16	NCT02884206
Zensun Sci. & Tech. Co., Ltd.	Recombinant human Neuregulin for injection	—	COMPLETED	2022-04-12	NCT04468529
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2022-03-27	NCT03619213
Novartis	LCZ696	—	COMPLETED	2022-01-03	NCT02678312
Johnson & Johnson	Canagliflozin 100 mg	—	COMPLETED	2021-11-09	NCT04252287
Otsuka Pharmaceutical Co., Ltd.	Tolvaptan	Vasopressin V2 Receptor Antagonist [EPC]	COMPLETED	2021-07-11	NCT03255226
scPharmaceuticals, Inc.	—	—	COMPLETED	2021-06-24	NCT03458325
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2021-05-28	NCT04157751
Novartis	LCZ696	—	COMPLETED	2021-05-25	NCT03917459
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2021-04-26	NCT03057951
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2020-12-30	NCT03884504
Cytokinetics	Omecamtiv Mecarbil	—	COMPLETED	2020-09-14	NCT02929329
Otsuka Pharmaceutical Co., Ltd.	OPC-61815	—	COMPLETED	2020-07-21	NCT03772041
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2020-07-09	NCT03877224
Otsuka Pharmaceutical Co., Ltd.	OPC-61815 injection	—	COMPLETED	2020-06-30	NCT03962101
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2020-05-21	NCT03332212
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2020-05-01	NCT03057977
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2020-03-07	NCT03877237
Mesoblast, Inc.	Rexlemestrocel-L	—	COMPLETED	2020-01-30	NCT02032004
Novartis	sacubitril/valsartan	—	COMPLETED	2019-10-28	NCT03066804
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2019-10-04	NCT03448406
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2019-09-30	NCT03448419
Dr. F. Köhler Chemie GmbH	Custodiol-N	—	COMPLETED	2019-09-02	NCT02869022
AstraZeneca	Dapagliflozin	SGLT2/hepatic glucose production/insulin sensitivity/intestinal absorption of glucose	COMPLETED	2019-07-17	NCT03036124
Merck	Vericiguat	Soluble Guanylate Cyclase Stimulator [EPC]	COMPLETED	2019-06-18	NCT02861534
Novartis	LCZ696	—	COMPLETED	2019-06-07	NCT01920711
Novartis	LCZ696	—	COMPLETED	2019-02-08	NCT02468232
Johnson & Johnson	Rivaroxaban	Factor Xa Inhibitor [EPC]	COMPLETED	2018-04-19	NCT01877915
Novartis	LCZ696 (Sacubitril/Valsartan)	—	COMPLETED	2018-04-11	NCT02900378
Johnson & Johnson	Rivaroxaban, 10 mg	—	COMPLETED	2018-03-06	NCT02111564
Novartis	LCZ696	—	COMPLETED	2017-12-28	NCT02226120
Celyad Oncology SA	Injection of C3BS-CQR-1	—	COMPLETED	2017-08	NCT01768702
Novartis	RLX030	—	COMPLETED	2017-01-23	NCT01870778
scPharmaceuticals, Inc.	—	—	COMPLETED	2016-11	NCT02804282
Cardiovascular Clinical Sciences Inc	Tolvaptan or Samsca	—	COMPLETED	2016-07	NCT01584557
Vifor Pharma	Ferinject (ferric carboxymaltose)	—	COMPLETED	2016-05	NCT01394562
Cardiorentis	Ularitide	—	COMPLETED	2015-11	NCT01661634
scPharmaceuticals, Inc.	Fursemide Injection Solution for subcutaneous administration (80 mg)	—	COMPLETED	2015-10	NCT02329834
Novartis	Enalapril	—	COMPLETED	2015-10	NCT00853658
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Eplerenone	Aldosterone Antagonist [EPC]	COMPLETED	2015-09	NCT01115855
Abbott Medical Devices	—	—	COMPLETED	2015-04	NCT01786993
Abbott Medical Devices	—	—	COMPLETED	2014-08	NCT01362725
LoneStar Heart, Inc.	Standard medical therapy	—	COMPLETED	2014-04	NCT01311791
LivaNova	—	—	COMPLETED	2013-06	NCT02167789
Novartis	Aliskiren	—	COMPLETED	2012-08	NCT00894387
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2012-07	NCT00887237
LivaNova	—	—	COMPLETED	2012-03	NCT01193634
Lee's Pharmaceutical Limited	Levocarnitine Injection	—	COMPLETED	2012-03	NCT01580553
The Medicines Company	Clevidipine	Dihydropyridine Calcium Channel Blocker [EPC]	COMPLETED	2012-02	NCT00803634
LivaNova	—	—	COMPLETED	2011-06	NCT01169272
Celyad Oncology SA	C-Cure	—	COMPLETED	2010-07	NCT00810238
Biogen	tonapofylline	—	COMPLETED	2009-10-30	NCT00709865
Takeda	Candesartan	—	COMPLETED	2008-12	NCT00775840
Novo Nordisk	Ziltivekimab	—	TERMINATED	2026-09-03	NCT05636176
Lexicon Pharmaceuticals	Sotagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	TERMINATED	2020-07-08	NCT03315143
Lexicon Pharmaceuticals	Sotagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	TERMINATED	2020-06-05	NCT03521934
United Therapeutics	Oral treprostinil	—	TERMINATED	2019-12-03	NCT03037580
Novartis	LCZ696	—	TERMINATED	2019-11-19	NCT03909295
GE Healthcare	Iobenguane I -123 Injection	—	TERMINATED	2018-05-04	NCT02656329
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2017-08	NCT01541202
CardioKinetix, Inc	—	—	TERMINATED	2017-06	NCT01614652
Novartis	Serelaxin	—	TERMINATED	2017-03-27	NCT02007720
Novartis	Serelaxin	—	TERMINATED	2017-03-26	NCT02064868
BioControl Medical	—	—	TERMINATED	2015-12	NCT01303718
Medtronic Endovascular	—	—	TERMINATED	2015-03	NCT01844037
Boston Scientific Corporation	—	—	TERMINATED	2014-04	NCT01872234
Eurofarma Laboratorios S.A.	Diurisa®	—	TERMINATED	2013-03-01	NCT01210365
Biotronik, Inc.	—	—	TERMINATED	2013-03	NCT00683696
CardioKinetix, Inc	—	—	TERMINATED	2013-01	NCT01286116
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2012-06	NCT01439789
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2012-06	NCT01131637

Showing 100 of 172 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shandong Suncadia Medicine Co., Ltd.	HRS-7535 tablet	—	RECRUITING	2026-12	NCT06820099
Iperboreal Pharma Srl	PolyCore (Polydextrin, L-Carnitine, D-xylitol)	—	RECRUITING	2026-12	NCT03994874
Tasly Pharmaceutical Group Co., Ltd	Mesenchymal stem cells(HucMSCs)	—	RECRUITING	2026-12-31	NCT07265349
Shandong Suncadia Medicine Co., Ltd.	HRS-1893 Tablet	—	RECRUITING	2027-03	NCT07269717
Novo Nordisk	CDR132L	—	RECRUITING	2027-05-16	NCT06979375
Novo Nordisk	CDR132L	—	RECRUITING	2027-11-16	NCT06979362
Edgewise Therapeutics, Inc.	EDG-15400 25 mg	—	RECRUITING	2027-12	NCT07795814
Heartseed Inc.	—	—	RECRUITING	2028-01-01	NCT07347197
Pfizer	Low Dose PF-07328948	—	RECRUITING	2028-05-08	NCT06991257
Cardurion Pharmaceuticals, Inc.	CRD-4730	—	RECRUITING	2028-09	NCT07750873
35Pharma Inc., a GSK company	HS235	—	RECRUITING	2029-01	NCT07123779
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	18F-metaFluorobenzylguanidine	—	RECRUITING	2026-10-30	NCT06965621
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9057 injection set	—	RECRUITING	2026-09	NCT07318103
Cytokinetics	CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)	—	RECRUITING	2026-09	NCT06793371
Sinotau Pharmaceutical Group	Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging	—	RECRUITING	2026-08	NCT07443696
Sardocor Corp.	SRD-001	—	RECRUITING	2025-12-31	NCT04703842
Tectonic Therapeutic	TX000045- Dose A	—	ACTIVE NOT RECRUITING	2026-11-24	NCT06616974
BioCardia, Inc.	—	—	ACTIVE NOT RECRUITING	2026-12	NCT05925608
Bristol-Myers Squibb	BMS-986435	—	ACTIVE NOT RECRUITING	2026-12-14	NCT06122779
HELP Therapeutics Co., Ltd.	HiCM-188 therapy	—	ACTIVE NOT RECRUITING	2026-11-10	NCT06340048
AskBio Inc	AB-1002	—	ACTIVE NOT RECRUITING	2026-10-31	NCT05598333
Salubris Biotherapeutics Inc	JK07	—	ACTIVE NOT RECRUITING	2026-10-31	NCT06369298
Innovent Biologics (Suzhou) Co. Ltd.	IBI362	—	ACTIVE NOT RECRUITING	2026-09-24	NCT06862908
Implicit Bioscience	Atibuclimab (IC14)	—	ACTIVE NOT RECRUITING	2026-04-30	NCT06556810
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531	—	ACTIVE NOT RECRUITING	2026-01	NCT06391710
Tasly Pharmaceutical Group Co., Ltd	Low dose Jia Shen Tablet	—	NOT YET RECRUITING	2026-12-31	NCT06669169
HELP Therapeutics Co., Ltd.	low dose CABG+iPSC-CMs	—	NOT YET RECRUITING	2027-12	NCT06866600
HELP Therapeutics Co., Ltd.	HiCM-188 Cells	—	NOT YET RECRUITING	2028-05	NCT07646210
AnaCardio AB	AC01	—	NOT YET RECRUITING	2028-07-30	NCT07584967
HELP Therapeutics Co., Ltd.	HiCM-188 Chitosan Patch	—	NOT YET RECRUITING	2028-10-20	NCT07471698
Eli Lilly	Bimagrumab	—	NOT YET RECRUITING	2029-07	NCT07920887
Akros Pharma Inc.	JTT-861 Capsules	—	COMPLETED	2026-05-18	NCT06017609
AstraZeneca	AZD5462	—	COMPLETED	2026-02-10	NCT06299826
Sarfez Pharmaceuticals, Inc.	Extended release torsemide	—	COMPLETED	2025-11-17	NCT06206512
Cardurion Pharmaceuticals, Inc.	Tovinontrine (CRD-750)	—	COMPLETED	2025-10-10	NCT06215911
Cardurion Pharmaceuticals, Inc.	Tovinontrine (CRD-750)	—	COMPLETED	2025-09-02	NCT06215586
Heartseed Inc.	HS-001 CS	—	COMPLETED	2025-07-31	NCT04945018
AstraZeneca	AZD3427	—	COMPLETED	2025-07-15	NCT05737940
Regeneron	REGN5381	—	COMPLETED	2025-06-02	NCT05353166
Tasly Pharmaceutical Group Co., Ltd	Qishen Yiqi dripping pills 4 bags/time	—	COMPLETED	2025-01-22	NCT04944706
Tasly Pharmaceutical Group Co., Ltd	Low dose QiShen YiQi Dripping Pills 3 bags	—	COMPLETED	2024-11-27	NCT04983043
River 2 Renal Corp.	R2R01	—	COMPLETED	2024-11-04	NCT06264310
Cardior Pharmaceuticals GmbH	CDR132L	—	COMPLETED	2024-09-26	NCT05350969
Imbria Pharmaceuticals, Inc.	IMB-1018972	—	COMPLETED	2024-08-06	NCT04826159
Bayer	Vericiguat (BAY1021189) 5 mg	—	COMPLETED	2024-07-29	NCT06195930
Rivus Pharmaceuticals, Inc.	HU6	—	COMPLETED	2024-05-24	NCT05284617
HELP Therapeutics Co., Ltd.	hPSC-CM Therapy	—	COMPLETED	2024-04-30	NCT03763136
Bristol-Myers Squibb	mavacamten	Cardiac Myosin Inhibitor [EPC]	COMPLETED	2024-02-26	NCT04766892
AstraZeneca	AZD9977	—	COMPLETED	2023-09-22	NCT04595370
Tenax Therapeutics, Inc.	Levosimendan	—	COMPLETED	2023-04-25	NCT03624010
Berlin Cures GmbH	BC 007	—	COMPLETED	2022-12-06	NCT04192214
Ionis Pharmaceuticals, Inc.	IONIS-AGT-LRx	—	COMPLETED	2022-10-19	NCT04836182
AstraZeneca	Verinurad	—	COMPLETED	2022-04-29	NCT04327024
Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.	TSG-01	—	COMPLETED	2022-04-22	NCT04515290
scPharmaceuticals, Inc.	—	—	COMPLETED	2022-04-18	NCT04593823
Bristol-Myers Squibb	BMS-986259	—	COMPLETED	2021-07-19	NCT04318093
AstraZeneca	AZD8601	—	COMPLETED	2021-06-30	NCT03370887
SQ Innovation, Inc.	Furosemide Injection Solution for subcutaneous administration (80 mg)	—	COMPLETED	2021-06-12	NCT04384653
Bayer	BAY 1753011	—	COMPLETED	2021-04-16	NCT03901729
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2021-03-12	NCT03153111
Tenax Therapeutics, Inc.	Levosimendan	—	COMPLETED	2020-04-07	NCT03541603
Intra-Cellular Therapies, Inc.	ITI-214	—	COMPLETED	2020-03-16	NCT03387215
Bristol-Myers Squibb	BMS-986231	—	COMPLETED	2019-12-11	NCT03730961
Bayer	Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets	—	COMPLETED	2019-10-15	NCT03547583
Akebia Therapeutics	IW-1973	—	COMPLETED	2019-08-19	NCT03254485
Bristol-Myers Squibb	HNO Donor	—	COMPLETED	2019-06-23	NCT03016325
Bristol-Myers Squibb	HNO Donor	—	COMPLETED	2019-05-10	NCT03357731
Novartis	CLR325	—	COMPLETED	2019-01-14	NCT02696967
Tau-MEDICAL Co., Ltd.	—	—	COMPLETED	2018-11-17	NCT03453853
Cardiora Pty. Ltd.	CRD-102	—	COMPLETED	2018-10-10	NCT03217331
Windtree Therapeutics	Istaroxime	—	COMPLETED	2018-08-14	NCT02617446
Bayer	Neladenoson bialanate (BAY1067197)	—	COMPLETED	2018-05-23	NCT03098979
Bayer	Neladenoson bialanate (BAY1067197)	—	COMPLETED	2018-03-28	NCT02992288
PhaseBio Pharmaceuticals Inc.	PB1046 Injection	—	COMPLETED	2017-12-06	NCT02808585
Stealth BioTherapeutics Inc.	elamipretide	—	COMPLETED	2017-11-27	NCT02914665
Stealth BioTherapeutics Inc.	4 mg elamipretide	—	COMPLETED	2017-09	NCT02788747
GSK	GSK2798745	—	COMPLETED	2017-08-21	NCT02497937
CardioCell LLC	Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)	—	COMPLETED	2017-05-11	NCT02467387
Stealth BioTherapeutics Inc.	elamipretide	—	COMPLETED	2017-05-04	NCT02814097
scPharmaceuticals, Inc.	—	—	COMPLETED	2016-08	NCT02804035
Capricor Inc.	Cenderitide	—	COMPLETED	2016-03-31	NCT02603614
Trevena Inc.	TRV027 Dose #1	—	COMPLETED	2016-03	NCT01966601
Bayer	BAY1142524	—	COMPLETED	2016-01	NCT02452515
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2015-10	NCT01213251
Novartis	RLX030 (serelaxin)	—	COMPLETED	2015-09	NCT01982292
Bayer	Vericiguat (BAY1021189) (1.25 mg)	—	COMPLETED	2015-08-18	NCT01951638
Cytokinetics	Omecamtiv Mecarbil Matrix F1 Formulation	—	COMPLETED	2015-07-22	NCT01786512
scPharmaceuticals, Inc.	Furosemide injection solution for subcutaneous administration (80 mg)	—	COMPLETED	2015-06	NCT02350725
Bristol-Myers Squibb	CXL-1427	—	COMPLETED	2015-05-31	NCT02157506
Bayer	Vericiguat (BAY1021189) (1.25 mg)	—	COMPLETED	2015-05-14	NCT01951625
Capricor Inc.	Cenderitide	—	COMPLETED	2015-04-02	NCT02359227
Celladon Corporation	—	—	COMPLETED	2015-02	NCT01643330
Bayer	BAY1067197 (10 mg)	—	COMPLETED	2015-01-29	NCT02040233
Bayer	BAY94-8862	—	COMPLETED	2015-01-23	NCT01955694
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2014-11-11	NCT01807221
Bayer	BAY1067197 (treatment 2)	—	COMPLETED	2014-09-09	NCT01945606
Novartis	Serelaxin	—	COMPLETED	2014-08	NCT02002702
Cyberonics, Inc.	—	—	COMPLETED	2014-04	NCT01823887
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2014-01	NCT01112579
Cytokinetics	Omecamtiv mecarbil	—	COMPLETED	2013-04	NCT01300013

Showing 100 of 104 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Chengdu Suncadia Medicine Co., Ltd.	HRS-5765 Tablet	—	RECRUITING	2026-12	NCT07551167
Novo Nordisk	CDR132L (i.v.)	—	RECRUITING	2026-12-31	NCT07656454
Novo Nordisk	NNC0537-1482	—	RECRUITING	2027-01-15	NCT07218627
Eli Lilly	LY3971297	—	RECRUITING	2027-11	NCT07547540
Madrigal Pharmaceuticals, Inc.	Resmetirom	Thyroid Hormone Receptor beta Agonist [EPC]	RECRUITING	2027-11	NCT07830758
Shandong Suncadia Medicine Co., Ltd.	HRS-7156	—	RECRUITING	2026-09	NCT07601087
Tasly Pharmaceutical Group Co., Ltd	Jia Shen Tablet	—	RECRUITING	2026-06-30	NCT06348498
Secretome Therapeutics	STM01	—	RECRUITING	2025-12-15	NCT06560762
Sardocor Corp.	AAV1/SERCA2a	—	RECRUITING	2025-08	NCT06061549
Vasa Therapeutics	VS-041	—	ACTIVE NOT RECRUITING	2026-11	NCT07219511
Fujian Shengdi Pharmaceutical Co., Ltd.	[14C]HRS-9057	—	ACTIVE NOT RECRUITING	2026-08-11	NCT07681479
Viscofan	—	—	NOT YET RECRUITING	2026-12-31	NCT06956807
Addpharma Inc.	AD-118, AD-1181	—	NOT YET RECRUITING	2026-08	NCT07717749
Beijing Suncadia Pharmaceuticals Co., Ltd	SHR-4658 Injection.	—	NOT YET RECRUITING	2026-06	NCT07230145
Addpharma Inc.	AD-118, AD-1181	—	NOT YET RECRUITING	2026-05	NCT07476157
R3 Stem Cell	Amniotic and Umbilical Cord Tissue Procedure	—	NOT YET RECRUITING	2024-03-20	NCT03899298
Beijing Suncadia Pharmaceuticals Co., Ltd	SHR-6934 injection	—	COMPLETED	2026-05-10	NCT06700083
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9057	—	COMPLETED	2025-10-29	NCT06506994
Thryv Therapeutics, Inc.	THRV-1268	—	COMPLETED	2025-10-20	NCT07186946
AstraZeneca	AZD5462 film-coated tablet	—	COMPLETED	2025-06-25	NCT06989983
Novo Nordisk	NNC0537-1482	—	COMPLETED	2025-05-04	NCT06625307
Humanis Saglık Anonim Sirketi	Sacubitril and Valsartan-Test product	—	COMPLETED	2025-01-20	NCT06922253
ModernaTX, Inc.	mRNA-0184	—	COMPLETED	2024-12-17	NCT05659264
Bayer	Formulation 1	—	COMPLETED	2024-09-30	NCT06474208
AskBio Inc	3 x 10e13vg AB-1002	—	COMPLETED	2024-08-20	NCT04179643
scPharmaceuticals, Inc.	SCP-111	—	COMPLETED	2024-06-14	NCT06167707
Eli Lilly	LY3461767	—	COMPLETED	2024-05-09	NCT04840914
Novartis	XXB750	—	COMPLETED	2024-01-18	NCT05328752
Bayer	Finerenone (BAY94-8862): intervention A	—	COMPLETED	2023-07-28	NCT07116512
AstraZeneca	AZD3427	—	COMPLETED	2022-09-14	NCT04630067
Alleviant Medical, Inc.	—	—	COMPLETED	2022-08-22	NCT05501652
Cardurion Pharmaceuticals, Inc.	CRD-740	—	COMPLETED	2022-08-03	NCT05437094
Alleviant Medical, Inc.	—	—	COMPLETED	2022-03-10	NCT05133089
Pfizer	Prazosin HCl 2mg	—	COMPLETED	2022-02-15	NCT04967443
Chong Kun Dang Pharmaceutical	D113	—	COMPLETED	2022-01-18	NCT05089279
Bayer	Vericiguat (BAY1021189) - Intervention A	—	COMPLETED	2021-12-22	NCT05086952
Boryung Pharmaceutical Co., Ltd	BR1016C	—	COMPLETED	2021-12-18	NCT05102266
Boryung Pharmaceutical Co., Ltd	BR1016A	—	COMPLETED	2021-12-14	NCT05102903
AstraZeneca	Treatment A	—	COMPLETED	2021-09-03	NCT04798222
Alleviant Medical, Inc.	—	—	COMPLETED	2021-08-16	NCT04583527
SQ Innovation, Inc.	—	—	COMPLETED	2021-08-13	NCT04846816
AstraZeneca	AZD4831	—	COMPLETED	2021-03-11	NCT04232345
Bayer	Pecavaptan (BAY1753011)	—	COMPLETED	2021-01-22	NCT05599997
Triple-Gene, LLC	INXN-4001	—	COMPLETED	2020-03-04	NCT03409627
Cardior Pharmaceuticals GmbH	CDR132L	—	COMPLETED	2020-01-31	NCT04045405
BioVentrix	—	—	COMPLETED	2019-12	NCT02553785
Olatec Therapeutics LLC	dapansutrile capsules	—	COMPLETED	2019-11-21	NCT03534297
Bristol-Myers Squibb	BMS-986231	—	COMPLETED	2019-08-29	NCT03515980
Bristol-Myers Squibb	BMS-986231 Formulation A	—	COMPLETED	2019-07-29	NCT03891108
AstraZeneca	AZD9977	—	COMPLETED	2019-05-02	NCT03801967
AstraZeneca	Treatment A	—	COMPLETED	2019-04-16	NCT03804645
AstraZeneca	AZD9977	—	COMPLETED	2019-04-01	NCT03843060
Bristol-Myers Squibb	BMS-986231	—	COMPLETED	2018-10-22	NCT03332186
Bial - Portela C S.A.	BIA 5-1058	—	COMPLETED	2018-10-05	NCT03489005
Ventrix, Inc.	VentriGel	—	COMPLETED	2018-09-05	NCT02305602
Otsuka Pharmaceutical Co., Ltd.	OPC-61815 16mg	—	COMPLETED	2018-07-05	NCT03510663
Amgen	AMG 986	—	COMPLETED	2018-03-12	NCT03318809
Sarfez Pharmaceuticals, Inc.	Demadex 20mg Tablet	—	COMPLETED	2017-07-20	NCT03214874
GSK	—	—	COMPLETED	2017-02-22	NCT02135861
GSK	GSK2798745 Micronized API without SLS and hypermellose (Tablet A)	—	COMPLETED	2016-12	NCT02925546
Acorda Therapeutics	GGF2	—	COMPLETED	2016-05	NCT01944683
Arbor Pharmaceuticals, Inc.	BiDil XR	—	COMPLETED	2016-04	NCT02522208
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2015-12	NCT01365234
Stealth BioTherapeutics Inc.	MTP-131	—	COMPLETED	2015-04	NCT02388464
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2015-01-22	NCT04722484
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2015-01-21	NCT04722562
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2014-09-16	NCT04881994
Bristol-Myers Squibb	CXL-1427 Ascending Dose	—	COMPLETED	2014-04	NCT02819271
CareLigo AB	—	—	COMPLETED	2013-12-18	NCT03655496
Harvest Technologies	—	—	COMPLETED	2013-08	NCT01299324
Cytokinetics	AMG 423	—	COMPLETED	2013-01	NCT01737866
Acorda Therapeutics	Glial growth factor 2/ Neuregulin 1β3	—	COMPLETED	2012-12	NCT01258387
Bayer	BAY94-8862 (1.25mg)	—	COMPLETED	2012-11-28	NCT01687920
Sorbent Therapeutics	CLP	—	COMPLETED	2012-09	NCT01598740
Trevena Inc.	TRV120027	—	COMPLETED	2012-05	NCT01444872
Bial - Portela C S.A.	BIA 5-1058	—	COMPLETED	2012-01	NCT02151994
Medispec	—	—	COMPLETED	2012-01	NCT01251185
Juventas Therapeutics, Inc.	ACRX-100	—	COMPLETED	2012-01	NCT01082094
Nile Therapeutics	Cenderitide	—	COMPLETED	2011-10	NCT01316432
GSK	—	—	COMPLETED	2011-08	NCT01277679
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2011-05-05	NCT04908436
Corimmun GmbH	COR-1	—	COMPLETED	2010-01	NCT01043146
Lantheus Medical Imaging	LMI 1195-101	—	COMPLETED	2009-11	NCT00891241
GSK	SK&F-105517-D 10 mg capsule	—	COMPLETED	2009-08-21	NCT00742508
Bial - Portela C S.A.	BIA-5-453	—	COMPLETED	2008-10	NCT03014375
Bial - Portela C S.A.	BIA 5-453	—	COMPLETED	2008-08-14	NCT03090568
Bial - Portela C S.A.	BIA 5-453	—	COMPLETED	2008-08-12	NCT03090724
AstraZeneca	AZD3427	—	TERMINATED	2025-08-21	NCT06611423
35Pharma Inc	HS135	—	TERMINATED	2025-07-29	NCT06581159
AstraZeneca	AZD5462	—	TERMINATED	2025-05-29	NCT06639087
Bayer	BAY2413555 Dose 1	—	TERMINATED	2023-03-31	NCT05532046
GSK	GSK3884464	—	TERMINATED	2022-08-05	NCT05044325
AstraZeneca	AZD9977	—	TERMINATED	2020-03-31	NCT03682497
Amgen	AMG 986 IV	—	TERMINATED	2019-04-18	NCT03276728
Bristol-Myers Squibb	BMS-986224	—	TERMINATED	2019-04-17	NCT03281122
Merck	MK-7145	—	TERMINATED	2014-12-17	NCT01558674
Medtronic BRC	—	—	TERMINATED	2014-05	NCT01509495
Salubris Biotherapeutics Inc	JK07	—	WITHDRAWN	2023-05-26	NCT05322616
AstraZeneca	AZD3427	—	WITHDRAWN	2022-08-02	NCT04890548
Sequana Medical N.V.	—	—	WITHDRAWN	2020-12-31	NCT03032211

Novel Heart Failure Drugs by Company (New molecular entities)

2 companies have an FDA-approved novel drug for Heart Failure.

Roche 1 drug

ACTIVASE

ALTEPLASE

BLA 1987

LEXICON PHARMS INC 1 drug

INPEFA

SOTAGLIFLOZIN

NDA 2023

Reformulations (29 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.